These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38837973)

  • 1. Day 3 parasitemia and Plasmodium falciparum Kelch 13 mutations among uncomplicated malaria patients treated with artemether-lumefantrine in Adjumani district, Uganda.
    Angwe MK; Mwebaza N; Nsobya SL; Vudriko P; Dralabu S; Omali D; Tumwebaze MA; Ocan M
    PLoS One; 2024; 19(6):e0305064. PubMed ID: 38837973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Day 3 parasitemia and
    Angwe MK; Mwebaza N; Nsobya SL; Vudriko P; Dralabu S; Omali D; Tumwebaze MA; Ocan M
    medRxiv; 2024 Apr; ():. PubMed ID: 38712186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of arps10, fd, pfmdr-2, pfcrt and pfkelch13 gene mutations in Plasmodium falciparum parasite population in Uganda.
    Ocan M; Ashaba FK; Mwesigwa S; Edgar K; Kamya MR; Nsobya SL
    PLoS One; 2022; 17(5):e0268095. PubMed ID: 35511795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study.
    Uwimana A; Umulisa N; Venkatesan M; Svigel SS; Zhou Z; Munyaneza T; Habimana RM; Rucogoza A; Moriarty LF; Sandford R; Piercefield E; Goldman I; Ezema B; Talundzic E; Pacheco MA; Escalante AA; Ngamije D; Mangala JN; Kabera M; Munguti K; Murindahabi M; Brieger W; Musanabaganwa C; Mutesa L; Udhayakumar V; Mbituyumuremyi A; Halsey ES; Lucchi NW
    Lancet Infect Dis; 2021 Aug; 21(8):1120-1128. PubMed ID: 33864801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine.
    Straimer J; Gandhi P; Renner KC; Schmitt EK
    J Infect Dis; 2022 Apr; 225(8):1411-1414. PubMed ID: 34216470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of in vivo selection for K13 mutations after artemether-lumefantrine treatment in Uganda.
    Balikagala B; Mita T; Ikeda M; Sakurai M; Yatsushiro S; Takahashi N; Tachibana SI; Auma M; Ntege EH; Ito D; Takashima E; Palacpac NM; Egwang TG; Onen JO; Kataoka M; Kimura E; Horii T; Tsuboi T
    Malar J; 2017 Jan; 16(1):23. PubMed ID: 28068997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of K13 mutations in Plasmodium falciparum persisting after artemisinin combination therapy treatment of Kenyan children.
    Muwanguzi J; Henriques G; Sawa P; Bousema T; Sutherland CJ; Beshir KB
    Malar J; 2016 Jan; 15():36. PubMed ID: 26801909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends of Plasmodium falciparum molecular markers associated with resistance to artemisinins and reduced susceptibility to lumefantrine in Mainland Tanzania from 2016 to 2021.
    Bakari C; Mandara CI; Madebe RA; Seth MD; Ngasala B; Kamugisha E; Ahmed M; Francis F; Bushukatale S; Chiduo M; Makene T; Kabanywanyi AM; Mahende MK; Kavishe RA; Muro F; Mkude S; Mandike R; Molteni F; Chacky F; Bishanga DR; Njau RJA; Warsame M; Kabula B; Nyinondi SS; Lucchi NW; Talundzic E; Venkatesan M; Moriarty LF; Serbantez N; Kitojo C; Reaves EJ; Halsey ES; Mohamed A; Udhayakumar V; Ishengoma DS
    Malar J; 2024 Mar; 23(1):71. PubMed ID: 38461239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Plasmodium falciparum k13 gene polymorphisms from Kisii County, Kenya during an era of artemisinin-based combination therapy deployment.
    Maniga JN; Samuel M; John O; Rael M; Muchiri JN; Bwogo P; Martin O; Sankarapandian V; Wilberforce M; Albert O; Onkoba SK; Adebayo IA; Adeyemo RO; Akinola SA
    Malar J; 2023 Mar; 22(1):87. PubMed ID: 36894982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. K13 mutations and pfmdr1 copy number variation in Plasmodium falciparum malaria in Myanmar.
    Win AA; Imwong M; Kyaw MP; Woodrow CJ; Chotivanich K; Hanboonkunupakarn B; Pukrittayakamee S
    Malar J; 2016 Feb; 15():110. PubMed ID: 26911145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria from three highly malarious states in India.
    Bharti PK; Shukla MM; Ringwald P; Krishna S; Singh PP; Yadav A; Mishra S; Gahlot U; Malaiya JP; Kumar A; Prasad S; Baghel P; Singh M; Vadadi J; Singh MP; Bustos MD; Ortega LI; Christophel EM; Kashyotia SS; Sonal GS; Singh N
    Malar J; 2016 Oct; 15(1):498. PubMed ID: 27737665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of association between polymorphisms in the K13 gene and the presence of Plasmodium falciparum parasites at day 3 after treatment with artemisinin derivatives in Senegal.
    Madamet M; Kounta MB; Wade KA; Lo G; Diawara S; Fall M; Bercion R; Nakoulima A; Fall KB; Benoit N; Gueye MW; Fall B; Diatta B; Pradines B
    Int J Antimicrob Agents; 2017 Jun; 49(6):754-756. PubMed ID: 28450175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of 3 and 5 day courses of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar.
    Tun KM; Jeeyapant A; Myint AH; Kyaw ZT; Dhorda M; Mukaka M; Cheah PY; Imwong M; Hlaing T; Kyaw TH; Ashley EA; Dondorp A; White NJ; Day NPJ; Smithuis F
    Malar J; 2018 Jul; 17(1):258. PubMed ID: 29996844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Detection of Residual Parasitemia after Pyronaridine-Artesunate or Artemether-Lumefantrine Treatment of Uncomplicated
    Roth JM; Sawa P; Omweri G; Makio N; Osoti V; de Jong MD; Schallig HDFH; Mens PF
    Am J Trop Med Hyg; 2018 Oct; 99(4):970-977. PubMed ID: 30105967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether-lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tanzania: a randomized controlled trial.
    Mhamilawa LE; Ngasala B; Morris U; Kitabi EN; Barnes R; Soe AP; Mmbando BP; Björkman A; Mårtensson A
    Malar J; 2020 Jun; 19(1):216. PubMed ID: 32576258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Ugandan Children.
    Yeka A; Wallender E; Mulebeke R; Kibuuka A; Kigozi R; Bosco A; Kyambadde P; Opigo J; Kalyesubula S; Senzoga J; Vinden J; Conrad M; Rosenthal PJ
    J Infect Dis; 2019 Mar; 219(7):1112-1120. PubMed ID: 30418593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Failure in a UK Malaria Patient Harboring Genetically Variant Plasmodium falciparum From Uganda With Reduced In Vitro Susceptibility to Artemisinin and Lumefantrine.
    van Schalkwyk DA; Pratt S; Nolder D; Stewart LB; Liddy H; Muwanguzi-Karugaba J; Beshir KB; Britten D; Victory E; Rogers C; Millard J; Brown M; Nabarro LE; Taylor A; Young BC; Chiodini PL; Sutherland CJ
    Clin Infect Dis; 2024 Feb; 78(2):445-452. PubMed ID: 38019958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of artemisinin-based combination treatment failure in patients returning from sub-Saharan Africa with P. falciparum malaria.
    Grossman T; Vainer J; Paran Y; Studentsky L; Manor U; Dzikowski R; Schwartz E
    J Travel Med; 2023 Dec; 30(8):. PubMed ID: 37606241
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Montenegro M; Neal AT; Posada M; De Las Salas B; Lopera-Mesa TM; Fairhurst RM; Tobon-Castaño A
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No polymorphisms in K13-propeller gene associated with artemisinin resistance in Plasmodium falciparum isolated from Brazzaville, Republic of Congo.
    Mayengue PI; Niama RF; Kouhounina Batsimba D; Malonga-Massanga A; Louzolo I; Loukabou Bongolo NC; Macosso L; Ibara Ottia R; Kimbassa Ngoma G; Dossou-Yovo LR; Pembet Singana B; Ahombo G; Sekangue Obili G; Kobawila SC; Parra HJ
    BMC Infect Dis; 2018 Oct; 18(1):538. PubMed ID: 30373565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.